Mereo BioPharma Group plc Stock London S.E.
Equities
MPH
GB00BZ4G2K23
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- GBX | -.--% | -10.17% | -.--% |
Sales 2024 * | 27.5M 34.35M | Sales 2025 * | 12.5M 15.61M | Capitalization | 308M 385M |
---|---|---|---|---|---|
Net income 2024 * | -8M -9.99M | Net income 2025 * | -28M -34.98M | EV / Sales 2024 * | 6.53 x |
Net cash position 2024 * | 128M 161M | Net cash position 2025 * | 142M 178M | EV / Sales 2025 * | 13.3 x |
P/E ratio 2024 * |
-293
x | P/E ratio 2025 * |
-59.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.94% |
Managers | Title | Age | Since |
---|---|---|---|
John P. Richard
FOU | Founder | 66 | 15-02-28 |
Founder | 64 | 15-07-09 | |
Charles Sermon
FOU | Founder | 55 | 15-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 19-04-22 |
Director/Board Member | - | 22-11-09 | |
Director/Board Member | 59 | 19-04-22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- MREO Stock
- MPH Stock